Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA) John E. Harris, MD, PhD, Mehdi Rashighi,

Slides:

Advertisements

Similar presentations

Successful treatment of corticosteroid-resistant ophiasis-type alopecia areata (AA) with platelet-rich plasma (PRP) Jeff Donovan, MD, PhD, FRCPC JAAD.

Advertisements

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Clinical efficacy of diphenylcyclopropenone in alopecia areata: Retrospective data analysis of 50 patients Katherine Chiang, BSE, Natasha Atanaskova.

Lesions referred to dermatology in the Department of Veterans Affairs (VA) health system: A retrospective chart review Katherine R. Grey, BA, Jaime L.

Hydroxychloroquine is ineffective in treatment of alopecia totalis and extensive alopecia areata: A case series of 8 patients Christoffer V. Nissen,

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo Stefan G. Vanderweil, MD, Shinya.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis Yasuhito Hamaguchi,

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Volume 3, Issue 6, Pages (November 2017)

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Sirolimus for acute pemphigus vulgaris: A case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection

Bioimpedance measurement as an assessment of margin positivity in Mohs surgical specimens of nonmelanoma skin cancer: Management implications Ryan M.

308-nm excimer laser therapy in alopecia areata

Successful treatment of corticosteroid-resistant ophiasis-type alopecia areata (AA) with platelet-rich plasma (PRP) Jeff Donovan, MD, PhD, FRCPC JAAD.

The Vitiligo Extent Score (VES) and the VESplus are responsive instruments to assess global and regional treatment response in patients with vitiligo

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Reply to: “A note on normality”

Alopecia areata Journal of the American Academy of Dermatology

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open- label extension study with optional narrow-band ultraviolet.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Muhammed Razmi T, MD, DNB, Davinder Parsad, MD, Sendhil M. Kumaran, MD

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Repigmentation of hair associated with melanoma in situ of scalp

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity James P. Strassner, BS, Mehdi Rashighi, MD, Maggi.

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Socioeconomic and geographic barriers to dermatology care in urban and rural US populations Toral Vaidya, MPH, Lindsey Zubritsky, MD, Ali Alikhan, MD,

Infectious rash after riding elephants

Molluscum contagiosum infection during the treatment of vitiligo with tacrolimus ointment Bong Kyun Ahn, MD, Byoung-Dae Kim, MD, Sang Ju Lee, MD, Seung.

Lip edema Journal of the American Academy of Dermatology

Stephanie D. Gan, MD, Sarah H

Volume 4, Issue 10, Pages (November 2018)

Treatment of alopecia areata with simvastatin/ezetimibe

Eva Wang, BS, John Koo, MD, Elie Levy, MD

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Alopecia Areata Registry: An Overview

Study Designs in Patient-Oriented Research

Volume 4, Issue 7, Pages (August 2018)

Melanocyte Regeneration in Vitiligo Requires WNT beneath their Wings

Pooja H. Rambhia, BA, Ivan J. Stojanov, DMD, Joshua Arbesman, MD

Seasonal patterns in alopecia areata, totalis, and universalis

Medicaid acceptance among pediatric dermatologists

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Volume 3, Issue 6, Pages (November 2017)

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

A new oral anticoagulant in the setting of dermatologic surgery

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

A grayscale photograph with high dynamic range taken under a Wood's lamp for better recognition of vitiligo lesions Jung Min Bae, MD, PhD, Tae Young.

Pigmented purpuric dermatosis (capillaritis) induced by bezafibrate

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

Presentation transcript:

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA) John E. Harris, MD, PhD, Mehdi Rashighi, MD, Nhan Nguyen, MD, Ali Jabbari, MD, PhD, Grace Ulerio, BA, Raphael Clynes, MD, PhD, Angela M. Christiano, PhD, Julian Mackay-Wiggan, MD, MS Journal of the American Academy of Dermatology Volume 74, Issue 2, Pages 370-371 (February 2016) DOI: 10.1016/j.jaad.2015.09.073 Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Vitiligo repigmentation during treatment with ruxolitinib. Screening skin examination reveals near-complete depigmentation of the patient's face at baseline. The first evidence of skin repigmentation appeared after 12 weeks of therapy, which continued until week 20, when ruxolitinib was discontinued. Follow-up visit 12 weeks after stopping the treatment shows recurrent depigmentation in the majority of previously repigmented areas. Pigmented areas of the face were outlined using the freehand selection tool followed by calculation of the percent selected area using ImageJ software (National Institutes of Health, Bethesda, MD). Journal of the American Academy of Dermatology 2016 74, 370-371DOI: (10.1016/j.jaad.2015.09.073) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Decrease in serum CXCL10 after initiating treatment with ruxolitinib. Serum samples were analyzed by enzyme-linked immunosorbent assay. CXCL10 level was elevated and remained stable while the patient was taking placebo in the first trial, but decreased after initiating treatment with ruxolitinib. Journal of the American Academy of Dermatology 2016 74, 370-371DOI: (10.1016/j.jaad.2015.09.073) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions